CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG)

International Journal of Cancer

Volumn 138, Issue 1, 2016, Pages 171-181

  Balermpas, Panagiotis ^a,b   Rödel, Franz ^a,b   Rödel, Claus ^a,b   Krause, Mechthild ^a,c,d,e   Linge, Annett ^a,c,d   Lohaus, Fabian ^a,c,d   Baumann, Michael ^a,c,d,e   Tinhofer, Inge ^a,f   Budach, Volker ^a,f   Gkika, Eleni ^a,g   Stuschke, Martin ^a,g   Avlar, Melanie ^a,h   Grosu, Anca Lidia ^a,h   Abdollahi, Amir ^a,i   Debus, Jürgen ^a,i   Bayer, Christine ^a   Stangl, Stefan ^a   Belka, Claus ^a,j   Pigorsch, Steffi ^a,k   Multhoff, Gabriele ^a,k   Combs, Stephanie E ^a,k   Mönnich, David ^a,l   Zips, Daniel ^a,l   Fokas, Emmanouil ^a,b   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d Dresden Rossendorf   (Germany)

^e INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF DUISBURG ESSEN   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^j UNIVERSITY OF MUNICH   (Germany)

^k TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^l UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

more..

Author keywords

CD8; DKTK ROG; HPV; postoperative chemoradiotherapy; prognostic; SCCHN

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; CISPLATIN; PROTEIN P16; VIRUS DNA; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; DNA DETERMINATION; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; AGED; CANCER GRADING; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; COMPLICATION; GENETICS; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PHENOTYPE; POSTOPERATIVE CARE; PROGNOSIS; TREATMENT OUTCOME; VIROLOGY; VIRUS INFECTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PHENOTYPE; POSTOPERATIVE CARE; PROGNOSIS; TREATMENT OUTCOME; TUMOR VIRUS INFECTIONS;

EID: 84944255998     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29683     Document Type: Article

References (51)

1. Ferlay J, Shin HR, Bray F, et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Cooper JS, Pajak TF, Forastiere AA, et al., Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-44.
3. Bernier J, Domenge C, Ozsahin M, et al., Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-52.
4. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al., Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013; 31: 4550-9.
5. Chaturvedi AK, Engels EA, Pfeiffer RM, et al., Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-301.
6. Ang KK, Harris J, Wheeler R, et al., Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
7. Fakhry C, Westra WH, Li S, et al., Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-9.
8. Lohaus F, Linge A, Tinhofer I, et al., HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiother Oncol 2014; 113: 317-23.
9. Bhardwaj N., Harnessing the immune system to treat cancer. J Clin Invest 2007; 117: 1130-6.
10. Gaipl US, Multhoff G, Scheithauer H, et al., Kill and spread the word: Stimulation of antitumor immune responses in the context of radiotherapy. Immunotherapy 2014; 6: 597-610.
11. Adams S, Gray RJ, Demaria S, et al., Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014; 32: 2959-66.
12. Denkert C, Loibl S, Noske A, et al., Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-13.
13. Thomas NE, Busam KJ, From L, et al., Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol 2013; 31: 4252-9.
14. Gooden MJ, de Bock GH, Leffers N, et al., The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis. Br J Cancer 2011; 105: 93-103.
15. Balermpas P, Michel Y, Wangenblast J, et al., Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J cancer 2014; 110: 501-9.
16. Ogino T, Shigyo H, Ishii H, et al., HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 2006; 66: 9281-9.
17. Le QT, Shi G, Cao H, et al., Galectin-1: A link between tumor hypoxia and tumor immune privilege. J Clin Oncol 2005; 23: 8932-41.
18. Jung AC, Guihard S, Krugell S, et al., CD8-alpha T-cell infiltration in human papillomavirus-related oropharyngeal carcinoma correlates with improved patient prognosis. Int J Cancer 2013; 132: E26-36.
19. Distel LV, Fickenscher R, Dietel K, et al., Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: Prognostic impact may depend on type of treatment and stage of disease. Oral Oncol 2009; 45: E167-74.
20. Balermpas P, Michel Y, Wagenblast J, et al., Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer 2014; 110: 547
21. Dahlin AM, Henriksson ML, Van Guelpen B, et al., Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol 2011; 24: 671-82.
22. Lieberman J, Shankar P, Manjunath N, et al., Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 2001; 98: 1667-77.
23. Grabenbauer GG, Lahmer G, Distel L, et al., Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res 2006; 12: 3355-60.
24. Nedergaard BS, Ladekarl M, Thomsen HF, et al., Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer. Br J Cancer 2007; 97: 1135
25. Ducray F, de Reynies A, Chinot O, et al., An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. Mol Cancer 2010; 9: 234
26. Ginos MA, Page GP, Michalowicz BS, et al., Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 2004; 64: 55-63.
27. Rajjoub S, Basha SR, Einhorn E, et al., Prognostic significance of tumor-infiltrating lymphocytes in oropharyngeal cancer. Ear Nose Throat J 2007; 86: 506-11.
28. Pretscher D, Distel LV, Grabenbauer GG, et al., Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. BMC Cancer 2009; 9: 292
29. Balermpas P, Michel Y, Wagenblast J, et al., Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer 2014; 110: 501-9.
30. Deschoolmeester V, Baay M, Van Marck E, et al., Tumor infiltrating lymphocytes: An intriguing player in the survival of colorectal cancer patients. BMC Immunol 2010; 11: 19
31. Stone HB, Peters LJ, Milas L., Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst 1979; 63: 1229-35.
32. Burnette BC, Liang H, Lee Y, et al., The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 2011; 71: 2488-96.
33. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al., Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014; 74: 5458-68.
34. Deng L, Liang H, Burnette B, et al., Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014; 124: 687-95.
35. Zeng J, See AP, Phallen J, et al., Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013; 86: 343-9.
36. Dovedi SJ, Melis MH, Wilkinson RW, et al., Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood 2013; 121: 251-9.
37. Bauman JE, Ferris RL., Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. Cancer 2014; 120: 624-32.
38. Schoenfeld JD., Immunity in head and neck cancer. Cancer Immunol Res 2015; 3: 12-7.
39. Albers AE, Visus C, Tsukishiro T, et al., Alterations in the T-cell receptor variable beta gene-restricted profile of CD8+ T lymphocytes in the peripheral circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2006; 12: 2394-403.
40. Reichert TE, Strauss L, Wagner EM, et al., Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002; 8: 3137-45.
41. Kim JW, Tsukishiro T, Johnson JT, et al., Expression of pro- and antiapoptotic proteins in circulating CD8+ T cells of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2004; 10: 5101-10.
42. Czystowska M, Gooding W, Szczepanski MJ, et al., The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC. Clin Cancer Res 2013; 19: 889-99.
43. Lyford-Pike S, Peng S, Young GD, et al., Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013; 73: 1733-41.
44. Ndiaye C, Mena M, Alemany L, et al., HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: A systematic review and meta-analysis. Lancet Oncol 2014; 15: 1319-31.
45. Nordfors C, Grun N, Tertipis N, et al., CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. Eur J Cancer 2013; 49: 2522-30.
46. Nasman A, Romanitan M, Nordfors C, et al., Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS One 2012; 7: E38711
47. Ward MJ, Thirdborough SM, Mellows T, et al., Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer 2014; 110: 489-500.
48. Keck MK, Zuo Z, Khattri A, et al., Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res 2015; 21: 870-81.
49. Kong CS, Narasimhan B, Cao H, et al., The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2009; 74: 553-61.
50. Wansom D, Light E, Thomas D, Worden F, Prince M, Urba S, Chepeha D, Kumar B, Cordell K, Eisbruch A, Taylor J, Moyer J, et al., Infiltrating lymphocytes and human papillomavirus-16-associated oropharyngeal cancer. Laryngoscope 2012; 122: 121-7.
51. Lassen P, Eriksen JG, Hamilton-Dutoit S, et al., Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1992-8.